ライフサイエンスコーパス: cognitive impairment

1 ipants per arm in amyloid-beta-positive mild cognitive impairment).

2 lzheimer's disease, 14 amyloid-positive mild cognitive impairment).

3 een hearing loss, neural reorganisation, and cognitive impairment.

4 nked to schizophrenia, autism, epilepsy, and cognitive impairment.

5 cases, participants were persons with known cognitive impairment.

6 ic damage and neurodegeneration that lead to cognitive impairment.

7 ntify individuals at high risk of developing cognitive impairment.

8 nd exercise training for treating MS-related cognitive impairment.

9 ve function versus mild, moderate, or severe cognitive impairment.

10 y age-associated DNA damage accumulation and cognitive impairment.

11 significantly correlated with the degree of cognitive impairment.

12 d frailty without co-occurring disability or cognitive impairment.

13 ical Manual of Mental Disorders criteria for cognitive impairment.

14 ms in patients with MDD and produced minimal cognitive impairment.

15 ch test's performance for identifying severe cognitive impairment.

16 and synaptic gene sets) were associated with cognitive impairment.

17 psychosis, risk for psychosis in youths, and cognitive impairment.

18 in the relationship between hearing loss and cognitive impairment.

19 n, but described a variable correlation with cognitive impairment.

20 aking >=1 glaucoma medication, and having no cognitive impairment.

21 d reversed spontaneous pain and PNI-mediated cognitive impairment.

22 reased neuroinflammation in individuals with cognitive impairment.

23 e-induced blood-brain barrier disruption and cognitive impairment.

24 parison (MNC) to determine the prevalence of cognitive impairment.

25 curacy of 49 screening instruments to detect cognitive impairment.

26 on in people aged above 60 years old without cognitive impairment.

27 notypes related to psychiatric disorders and cognitive impairment.

28 e major mechanisms underlying stress-induced cognitive impairment.

29 zheimer's disease and their relationships to cognitive impairment.

30 ed with a lower risk of incident dementia or cognitive impairment.

31 iated with long-term neurologic deficits and cognitive impairment.

32 Screening instruments can adequately detect cognitive impairment.

33 ain atrophy in participants with and without cognitive impairment.

34 resistant seizures, developmental delay, and cognitive impairment.

35 ith Alzheimer disease (AD) dementia and mild cognitive impairment.

36 rebrovascular effects of APOE4 contribute to cognitive impairment.

37 Diabetes is an independent risk factor for cognitive impairment.

38 physical activity may reflect early signs of cognitive impairment.

39 in people with Alzheimer's Disease and Mild Cognitive Impairment.

40 ow increases that precedes tau pathology and cognitive impairment.

41 disability in activities of daily living and cognitive impairment.

42 rage NDVI, APOE epsilon4 carrier status, and cognitive impairment.

43 air genes were significantly associated with cognitive impairment.

44 ality and the WM dysconnectivity may lead to cognitive impairment.

45 nts with multiple system atrophy can develop cognitive impairment.

46 gnificantly associated with AD pathology and cognitive impairment.

47 ture positive neuropsychological testing for cognitive impairment.

48 epatitis C virus (HCV) coinfection increases cognitive impairment.

49 LLD participants met ADNI criteria for mild cognitive impairment.

50 tem cancer patients to manage cancer-related cognitive impairment.

51 and TBI in military veterans (mtTBI) without cognitive impairment.

52 ease duration was not found in patients with cognitive impairment.

53 D group that included participants with mild cognitive impairment.

54 ognitive function for older adults with mild cognitive impairment.

55 drome, a sex-linked disorder associated with cognitive impairment.

56 der, without recognized signs or symptoms of cognitive impairment.

57 eptional longevity & normal cognition versus cognitive impairment.

58 ures of Alzheimer's disease without signs of cognitive impairment.

59 fatigue, musculoskeletal pain, and perceived cognitive impairment.

60 differ regarding baseline data or premorbid cognitive impairments.

61 es in GMD, and those changes appear to drive cognitive impairments.

62 rtex (PFC), and this leads to behavioral and cognitive impairments.

63 that are centrally important to age-related cognitive impairments.

64 Critical illness can cause severe cognitive impairments.

65 athologies, cerebral insulin resistance, and cognitive impairments.

66 d (0.4 +/- 2.7%), amyloid-beta-negative mild cognitive impairment (-0.4 +/- 2.3%) or amyloid-beta-pos

67 ssociated with a reduced risk of dementia or cognitive impairment (12 trials; 92 135 participants) (7

68 patients vs four sedated patients) or severe cognitive impairments (16 nonsedated patients vs 17 seda

69 ps in the schizophrenia group: preadolescent cognitive impairment (19%), adolescent disruption of cog

70 l was observed in amyloid-beta-positive mild cognitive impairment (3.0 +/- 5.3%) and Alzheimer's dise

71 ce of dementia (or composite of dementia and cognitive impairment [3 trials]) on follow-up and were i

72 ed individuals and 204 individuals with mild cognitive impairment (320 [53%] were female) were classi

73 had normal cognitive function, 17% had mild cognitive impairment, 33% had moderate impairment, and 2

74 hs, 276 patients had frailty, disability, or cognitive impairment, 37 (13%) of whom had frailty alone

75 ing features ranging from epilepsy (32%) and cognitive impairment (49%) to exercise intolerance (25%)

76 dysfunction; (3) psychological disorder; (4) cognitive impairment; (5) failed social reconstruction;

77 mental delay (9/9), impaired language (9/9), cognitive impairment (8/9), ataxia (6/9), dysarthria in

78 45 patients with Parkinson's disease with no cognitive impairment, 86 with mild cognitive impairment,

79 In addition to cognitive impairment, a range of mental health disorders

80 ents were classified as none, mild, or major cognitive impairment according to the fifth version of t

81 l profile could be associated with different cognitive impairments across different children.

82 ith 107 repeats developed motor symptoms and cognitive impairment after 8 to 10 years.

83 an syndrome (AS) are characterized by severe cognitive impairments alongside an enhanced drive for so

84 e impairment (ALScn; n=13) and patients with cognitive impairment (ALSci; n=8).

85 divided into two subgroups: patients without cognitive impairment (ALScn; n=13) and patients with cog

86 rmacological interventions for amnestic mild cognitive impairment (aMCI) patients.

87 gitudinal study of people with amnestic mild cognitive impairment (aMCI) we assessed three parameters

88 e impaired group by clinical phenotype (mild cognitive impairment, amnestic dementia, and non-amnesti

89 ocial factors may play in the development of cognitive impairment among older adults.

90 aimed to identify the extent and patterns of cognitive impairment among those patients.

91 ity to prospectively assess patient-reported cognitive impairment among women with early breast cance

92 h Alzheimer's disease (n = 50 with late mild cognitive impairment and 71 with Alzheimer's dementia, a

93 ging and age-related conditions such as mild cognitive impairment and Alzheimer's disease.

94 e LATE-NC and one pure ADNC) donors had mild cognitive impairment and another two donors with LATE-NC

95 However, the genetic liability to cognitive impairment and apathy appears to be distinct f

96 Cognitive impairment and apathy were associated with red

97 erosis is unknown, as is their relevance for cognitive impairment and brain function.

98 Our aim was to investigate the cognitive impairment and cerebrospinal fluid biomarkers

99 with AD in comparison to patients with mild cognitive impairment and control subjects.

100 a risk factor for vascular contributions to cognitive impairment and dementia (VCID), particularly i

101 data provide evidence that the risk for mild cognitive impairment and dementia is increased in indivi

102 ly been associated to CSF biomarkers in mild cognitive impairment and dementia patients.

103 the most important protective factor against cognitive impairment and dementia, yet significant varia

104 itive decline might result in early onset of cognitive impairment and dementia.

105 ical cerebrovascular abnormalities, vascular cognitive impairment and dementia.

106 dromic/premotor stage and evolve, along with cognitive impairment and dysautonomia, as the disease pr

107 Diabetes is associated with cognitive impairment and greater risk for dementia, but

108 Cognitive Impairment and Imaging Correlates in End Stage

109 matory pathways that contribute to long-term cognitive impairment and memory loss.

110 model of temporal lobe epilepsy, and rescued cognitive impairment and transcriptomic alterations asso

111 biological pathways that are associated with cognitive impairment and used these results to construct

112 Therefore, abnormal glucose metabolism, cognitive impairment and widespread disruption of WM str

113 mentia and n = 14 with amyloid-positive mild cognitive impairment) and 29 healthy control subjects un

114 disposing factors (for example, pre-existing cognitive impairment) and precipitating factors (for exa

115 e with no cognitive impairment, 86 with mild cognitive impairment, and 17 with dementia.

116 e osteoporosis, hypotonic stature, seizures, cognitive impairment, and developmental delay.

117 control participants, participants with mild cognitive impairment, and participants with AD dementia;

118 stic cats (Felis catus) are known to develop cognitive impairment, and several small series have demo

119 associated with numerous symptoms, including cognitive impairment, and shortened lifespan.

120 ta levels become abnormal long before severe cognitive impairments appear, increasing evidence sugges

121 Cognitive impairments are a particularly disabling featu

122 Age-related cognitive impairments are associated with differentially

123 table cognitive impairments even if specific cognitive impairments are not an explicit part of their

124 Cognitive impairment as detected by the ECAS is a valid

125 tor, is being evaluated for the treatment of cognitive impairment associated with schizophrenia (CIAS

126 re 376 patients with frailty, disability, or cognitive impairment at 3-month follow-up.

127 oordinating Center on participants with mild cognitive impairment at baseline and either no neuritic

128 >=70 years who were free of both stroke and cognitive impairment at enrollment in a cognitive substu

129 d only selective cognitive impairments or no cognitive impairments at all.

130 icipants with a global CDR of 0.5 (i.e. mild cognitive impairment) at baseline, 126 with primary age-

131 ighest overall predictive ability for severe cognitive impairment (AUC, 0.81); a score of <=21 had a

132 (miRNA) expression, plasma inflammation, and cognitive impairment before and after therapy.

133 ters during their transitions from normal to cognitive impairment but remained stable over the entire

134 APOE4 carriers and more severe in those with cognitive impairment, but is not related to amyloid-beta

135 treatment of prepubertal mice prevented this cognitive impairment, but not increased frontal cortex 5

136 disease (AD) causes unrelenting, progressive cognitive impairments, but its course is heterogeneous,

137 lance of benefits and harms of screening for cognitive impairment cannot be determined.

138 ese data reveal a specific kind of transient cognitive impairment caused by IEDs and link this impair

139 Cancer-related cognitive impairment (CRCI) is common during adjuvant ch

140 , bipolar disorder, multiple sclerosis, mild cognitive impairment, dementia, and Parkinson's disease,

141 aracterized as cognitively stable (CS), mild cognitive impairment-DS (MCI-DS), possible AD dementia,

142 Other conditions have notable cognitive impairments even if specific cognitive impairm

143 new potential technique to understand human cognitive impairment for a range of neurological disease

144 ay a role in the elevated risk of developing cognitive impairment found among patients with CKD.

145 eral adverse events, serious adverse events, cognitive impairment, fractures, falls, syncope, hypoten

146 the most severe impaired domains in the mild cognitive impairment group, attention and visuospatial f

147 e most serious impaired domains in the major cognitive impairment group.

148 All patients with cognitive impairment had TDP-43 pathology in extramotor

149 all the time (HR, 1.46 [CI, 1.05 to 2.05]), cognitive impairment (HR, 1.49 [CI, 1.04 to 2.13]), or f

150 neurovascular effects that may contribute to cognitive impairment in Alzheimer's disease.

151 ood-brain barrier disruption associated with cognitive impairment in animal models of CKD.

152 The clinical epidemiological features of cognitive impairment in Chinese older adult patients und

153 -infected Children cohort showed significant cognitive impairment in combination antiretroviral thera

154 ved in Alzheimer's disease may contribute to cognitive impairment in drug-resistant temporal lobe epi

155 gic examination and which is associated with cognitive impairment in HIV.

156 importantly its dysfunction is implicated in cognitive impairment in humans.

157 ystematic review, we report the frequency of cognitive impairment in ICU survivors across various tim

158 rly life markedly reduces the probability of cognitive impairment in late life in Colombia.

159 ciations between education in early life and cognitive impairment in later life in Colombia.

160 stronger associations between PM2.5 and poor cognitive impairment in men than women.

161 irections for research into the treatment of cognitive impairment in MS that should set the stage for

162 The prevalence of cognitive impairment in multiple sclerosis varies across

163 gainst obesity-induced neuroinflammation and cognitive impairment in NLRP3-KO mice, we transplanted V

164 at it is possible to discriminate antecedent cognitive impairment in older adults before the onset of

165 lance of benefits and harms of screening for cognitive impairment in older adults.

166 (BP) is a known risk factor for mobility and cognitive impairment in older adults.

167 Cognitive impairment in participants with Down syndrome

168 and gene-level variants are associated with cognitive impairment in patients with hematologic malign

169 or the underlying white matter might affect cognitive impairment in patients with multiple system at

170 d to determine the pathological correlate of cognitive impairment in patients with non-demented ALS.

171 elopments in the treatment and management of cognitive impairment in people with MS.

172 ssociated comorbidities increase the risk of cognitive impairment in persons living with human immuno

173 ve function was measured with the Screen for Cognitive Impairment in Psychiatry in the psychosis coho

174 detection of psychosis risk and treatment of cognitive impairment in psychosis.

175 althy populations, but their contribution to cognitive impairment in schizophrenia has not been inves

176 Cognitive impairment in schizophrenia is a major contrib

177 co-occurrence of frailty with disability and cognitive impairment in survivors of critical illness.

178 l as enhanced the brain Abeta deposition and cognitive impairment in Tg-SwDI mice.

179 Here, investigating cognitive impairment in the largest number of pathologic

180 In CKD rats, we found cognitive impairment in the novel object recognition tes

181 ired participants and 100 patients with mild cognitive impairment in the Swedish BioFINDER study.

182 promising therapeutic target for attenuating cognitive impairment in VaD.

183 the combination of HF diet and VCID elicited cognitive impairments in all tests, in both sexes.

184 rogenesis as a potential target to normalize cognitive impairments in MS patients.

185 beginning 30 min post-injury, reversed early cognitive impairments in TBI mice and led to transient i

186 Factors associated with major cognitive impairment included age, education level, hist

187 the aim of identifying associations between cognitive impairment including memory impairment and alp

188 ative (17 with AD dementia and 199 with mild cognitive impairment), including (18)F-florbetapir PET,

189 een ST6GAL1 mutations and conversion of mild cognitive impairment into clinical Alzheimer's disease.

190 Cognitive impairment is a common and devastating manifes

191 Cognitive impairment is a frequent comorbidity, but the

192 Cognitive impairment is a key cause of disability after

193 Cognitive impairment is a well-known complication of dia

194 Cognitive impairment is an increasingly recognized major

195 Long-term cognitive impairment is common among ICU survivors, but

196 Despite this, the etiology of the cognitive impairment is poorly understood, and no satisf

197 Cognitive impairment is significantly improved with cure

198 e lowering for the prevention of dementia or cognitive impairment is unclear.

199 iduals with DS; however, its contribution to cognitive impairment is unresolved.

200 While IEDs are associated with transient cognitive impairments, it remains poorly understood why

201 en sustaining a sport-related concussion and cognitive impairment later in life.

202 thy people and patients exhibiting late mild cognitive impairment leading to Alzheimer disease.

203 lves severe fatigue, unrefreshing sleep, and cognitive impairment, leading to functional difficulties

204 Community-dwelling older adults with mild cognitive impairment living in an urban area in Chifeng,

205 t patients with VZV encephalitis suffer from cognitive impairment long time after acute disease.

206 al interventions are safe for cancer-related cognitive impairment management.

207 k, which in turn may have contributed to the cognitive impairments manifested in TBI patients.

208 Identifying heterogeneous cognitive impairment markers at an early stage is vital

209 Early identification of cognitive impairment may improve patient and caregiver h

210 and clinically diagnosed patients with mild cognitive impairment (MCI) (n = 178), AD dementia (n = 1

211 including cognitively unimpaired (CU), mild cognitive impairment (MCI) and AD dementia patients char

212 nosis of no cognitive impairment (NCI), mild cognitive impairment (MCI) and AD.

213 Memory disruption in mild cognitive impairment (MCI) and Alzheimer's disease (AD)

214 h subjective cognitive decline (SCD) or mild cognitive impairment (MCI) can serve to predict progress

215 l fluid (CSF) and blood KLK8 for AD and mild cognitive impairment (MCI) due to AD.

216 ake liberal use of the descriptive term mild cognitive impairment (MCI) for those with cognitive diff

217 ociations of sleep characteristics with mild cognitive impairment (MCI) have been examined in cross-s

218 treatment on incidence of dementia and mild cognitive impairment (MCI) in 9361 participants in the r

219 et Alzheimer disease (LOAD) preceded by mild cognitive impairment (MCI) is the most common type of de

220 y control participants, and a cohort of mild cognitive impairment (MCI) patients with four-year clini

221 ferences between healthy controls (HC), mild cognitive impairment (MCI) patients, and AD patients, an

222 Postmortem brains of mild cognitive impairment (MCI) rather than symptomatic AD pa

223 discovery [cognitively normal (CN), 19; mild cognitive impairment (MCI) risk, 43; MCI, 6] and replica

224 position related to the conversion from mild cognitive impairment (MCI) to Alzheimer disease (AD).

225 SCeVD (n = 22), preclinical AD (pAD) + mild cognitive impairment (MCI) without SCeVD (pAD/MCI withou

226 cross-sectional study, 14 patients with mild cognitive impairment (MCI), a prodromal stage to dementi

227 impaired participants and patients with mild cognitive impairment (MCI), AD dementia and non-AD neuro

228 ean age 63-69 years), participants with mild cognitive impairment (MCI), Alzheimer's disease, and fro

229 th hippocampal subfield analysis of AD, mild cognitive impairment (MCI), and healthy subjects.

230 ar dementia (VD), senile dementia (SD), mild cognitive impairment (MCI), and other neurodegenerative

231 four groups: Alzheimer's disease (AD), mild cognitive impairment (MCI), FCD and healthy controls.

232 et of CN participants who progressed to mild cognitive impairment (MCI), heightened memory awareness

233 individuals with Alzheimer's dementia, Mild Cognitive Impairment (MCI), or no cognitive impairment w

234 ion) of both dementia and its prodrome, mild cognitive impairment (MCI), which are characterized by d

235 in a large population of patients with mild cognitive impairment (MCI).

236 nitive impairment (motor neuron disease with cognitive impairment (MNDci)), behavioural impairment (m

237 ciated with brain disorders characterized by cognitive impairment, mood disturbances, or psychosis, s

238 n Fabry disease, and their correlations with cognitive impairment, mood, anxiety, disease severity an

239 was also related to lower risk of developing cognitive impairment, more so than grey matter volume.

240 We identified patients with cognitive impairment (motor neuron disease with cognitiv

241 It is associated with cognitive impairment, muscle hypotonia, heart defects, a

242 767 cognitively impaired participants (mild cognitive impairment n = 420, Alzheimer's disease dement

243 unimpaired (n = 153), or patients with mild cognitive impairment (n = 139) or Alzheimer's disease de

244 bodies (n = 1), Parkinson disease with mild cognitive impairment (n = 2), corticobasal syndrome (n =

245 es with a premortem clinical diagnosis of no cognitive impairment (NCI), mild cognitive impairment (M

246 n the brain are thought to contribute to the cognitive impairments observed in Alzheimer's disease pa

247 d cerebral amyloid angiopathy associate with cognitive impairment of similar magnitude to that associ

248 examined the direct effect of screening for cognitive impairment on patient outcomes, including pote

249 ears before the estimated median age at mild cognitive impairment onset of 44 years), although the ab

250 p with age, beta-amyloid pathology, and mild cognitive impairment or clinical AD diagnostic status.

251 bined group of participants with either mild cognitive impairment or dementia with Alzheimer's clinic

252 These effects were independent of cognitive impairment or total levodopa equivalent dose.

253 ldren with these networks had only selective cognitive impairments or no cognitive impairments at all

254 dicted, DLCO, or DLCO percentage predicted), cognitive impairment, or depression.

255 patients without previous diagnoses of ADRD, cognitive impairment, or neurological degeneration, who

256 accelerated p-tau217 compared to other mild cognitive impairment patients (beta = 0.79, P < 0.001).

257 Mild cognitive impairment patients who later converted to Alz

258 The FACT-Cog included the 20-item Perceived Cognitive Impairment (PCI) scale, our primary end point.

259 Post-stroke cognitive impairment (PSCI) is a major source of disabil

260 ability, there is an urgent need to identify cognitive impairments related to its use.

261 motherapy produces early, but not sustained, cognitive impairment relative to E, providing reassuranc

262 macological interventions for cancer-related cognitive impairment remain largely unknown.

263 d cognitive decline in normal aging and mild cognitive impairment remains elusive.

264 tress, likely contributing to stress-induced cognitive impairment.SIGNIFICANCE STATEMENT Repeated exp

265 ential mechanism contributing to age-related cognitive impairments.SIGNIFICANCE STATEMENT A high perc

266 in the number of patients with mild/moderate cognitive impairments (six nonsedated patients vs four s

267 use a neurodevelopmental disorder defined by cognitive impairment, social-communication disorder, and

268 The data was collected during a cognitive impairment study at NASA Langley Research Cent

269 e later-stage extracellular Abeta burden and cognitive impairment, suggesting that preclinical/prodro

270 Cognitive impairment symptoms were significantly higher

271 complement C1q ameliorates radiation-induced cognitive impairments, synaptic loss, and neuroinflammat

272 y distress syndrome had higher prevalence of cognitive impairment than mixed ICU patients at ICU disc

273 jetlag, social jetlag disorders) and causes cognitive impairments that are costly and long lasting.

274 herapy for the treatment of HIV-1 infection, cognitive impairments, that is, HIV-1-associated neuroco

275 ld cognitive impairment, with progression of cognitive impairment to AD associating with ongoing musc

276 lence and temporal trajectory of ICU-related cognitive impairment varies depending on the type of cog

277 education, the fully adjusted odds ratio for cognitive impairment was 0.57 (95% confidence interval:

278 The prevalence of cognitive impairment was 17.93% in the main analysis (n

279 Cognitive impairment was assessed among a subgroup of 55

280 Cognitive impairment was defined as the lowest tertile i

281 Cognitive impairment was detected in varying degrees in

282 infection alone, which strong suggests that cognitive impairment was driven by both HIV and HCV.Summ

283 The mean prevalence of cognitive impairment was higher with objective rather th

284 eenness (the highest vs. lowest quartile) on cognitive impairment was observed among the non-epsilon4

285 d baseline scores, the hazard of substantive cognitive impairment was reduced by 14% in those assigne

286 Rescue of cognitive impairments was achieved through pharmacologic

287 Diagnosis of neurological disorder or cognitive impairment were exclusion criteria.

288 w-up assessment, were assumed to have severe cognitive impairments were analyzed, but still no differ

289 el, <54 mg per deciliter) or level 3 (severe cognitive impairment) were low (icodec group, 0.53 event

290 are severe mental disorders associated with cognitive impairment, which is considered a major determ

291 istance accelerates progression of age-based cognitive impairment, which neuroimaging has linked to b

292 ith Parkinson's disease subsequently develop cognitive impairment, which often progresses to dementia

293 ative participants, or in patients with mild cognitive impairment who did not convert to Alzheimer's

294 rols, but also between individuals with Mild Cognitive Impairment who were later diagnosed with Alzhe

295 ntia, Mild Cognitive Impairment (MCI), or no cognitive impairment with high (HA-NCI) and low (LA-NCI)

296 vious studies have suggested higher rates of cognitive impairment with restrictive transfusion thresh

297 Anti-parallel dimers induced cognitive impairments with increased amyloidogenesis and

298 ic conditions are defined by the presence of cognitive impairment, with onset ranging from childhood,

299 a loss of muscle mass) in patients with mild cognitive impairment, with progression of cognitive impa

300 te of cognitive decline and risk of dementia/cognitive impairment without dementia did not differ by